MDXG - Mimedx Group Inc
IEX Last Trade
6.85
0.160 2.336%
Share volume: 2,194,989
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$6.69
0.16
2.39%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-11-02 | 2023-02-28 | 2023-05-02 | 2023-08-01 | 2023-10-30 | 2024-02-28 | 2024-04-30 | 2024-07-31 | |
| Assets | |||||||||
| Total Assets | 172.798 M | 171.430 M | 168.159 M | 176.378 M | 189.022 M | 239.047 M | 221.681 M | 230.183 M | |
| Current Assets | 136.040 M | 134.198 M | 131.702 M | 141.223 M | 154.502 M | 164.261 M | 138.853 M | 154.018 M | |
| Inventories | 13.976 M | 13.183 M | 14.657 M | 16.815 M | 19.068 M | 21.021 M | 24.454 M | 25.056 M | |
| Other Current Assets | 7.261 M | 11.277 M | 11.130 M | 6.793 M | 5.265 M | 7.369 M | 8.896 M | 7.127 M | |
| Short Term Investments | 7.261 M | 11.277 M | 11.130 M | 6.793 M | 5.265 M | 7.369 M | 8.896 M | 7.127 M | |
| Total Receivables | 41.586 M | 43.788 M | 44.694 M | 48.963 M | 49.005 M | 53.871 M | 57.016 M | 52.798 M | |
| Current Cash | 73.217 M | 65.950 M | 61.221 M | 68.652 M | 81.164 M | 82.000 M | 48.487 M | 69.037 M | |
| Total Non-current Assets | 36.758 M | 37.232 M | 36.457 M | 35.155 M | 34.520 M | 74.786 M | 82.828 M | 76.165 M | |
| Property Plant Equipment | 7.912 M | 7.856 M | 7.562 M | 7.261 M | 7.094 M | 6.974 M | 7.340 M | 6.822 M | |
| Other Assets | 150.000 K | 148.000 K | 147.000 K | 146.000 K | 149.000 K | 205.000 K | 1.251 M | 1.239 M | |
| Intangible Assets | 4.992 M | 5.852 M | 5.706 M | 5.565 M | 5.395 M | 5.257 M | 12.550 M | 12.047 M | |
| Goodwill | 19.976 M | 19.976 M | 19.976 M | 19.441 M | 19.441 M | 19.441 M | 19.441 M | 19.441 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 172.798 M | 171.430 M | 168.159 M | 176.378 M | 189.022 M | 239.047 M | 221.681 M | 230.183 M | |
| Total liabilities | 99.824 M | 96.924 M | 93.611 M | 96.550 M | 95.198 M | 96.330 M | 65.950 M | 62.143 M | |
| Total current liabilities | 45.858 M | 43.557 M | 40.870 M | 44.460 M | 43.627 M | 46.008 M | 42.221 M | 40.012 M | |
| Accounts Payable | 8.820 M | 8.847 M | 7.823 M | 8.150 M | 9.170 M | 9.048 M | 9.697 M | 7.603 M | |
| Other liabilities | 5.491 M | 4.773 M | 4.027 M | 3.252 M | 2.605 M | 2.223 M | 5.276 M | 3.882 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 1.000 M | 3.196 M | |
| Long term debt | 48.475 M | 48.594 M | 48.714 M | 48.838 M | 48.966 M | 48.099 M | 18.453 M | 18.249 M | |
| Other liabilities | 5.491 M | 4.773 M | 4.027 M | 3.252 M | 2.605 M | 2.223 M | 5.276 M | 3.882 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 72.974 M | 74.506 M | 74.548 M | 79.828 M | 93.824 M | 142.717 M | 155.731 M | 168.040 M | |
| Common stock | 113.448 M | 113.705 M | 114.399 M | 115.866 M | 116.298 M | 119.420 M | 146.405 M | 147.326 M | |
| Retained earnings | -191.492 M | -191.906 M | -196.889 M | -195.689 M | -187.155 M | -133.678 M | -124.417 M | -106.792 M |